Daiichi Sankyo Presents Late-Breaking Phase 1 Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer at the ESMO 2016 Congress
Preliminary trials for a new antibody drug shows patients tolerated the treatment well with a 90% disease control rate for gastric cancer patients.
Read Source
